Related Experiment Video
Updated: Jul 18, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Clopidogrel resistance?
Paul A Gurbel1, Udaya S Tantry
1Sinai Center for Thrombosis Research, Baltimore, MD 21215, USA. PGURBEL@LIFEBRIDGEHEALTH.ORG
Thrombosis Research
|November 18, 2006
Summary
Clopidogrel, a P2Y12 receptor inhibitor, is vital for preventing platelet aggregation. However, variable patient responses and nonresponsiveness to clopidogrel pose risks for ischemic events, prompting research into its metabolism.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Therapeutics
Background:
- Clopidogrel effectively inhibits platelet activation by blocking the P2Y12 receptor.
- Combination therapy with clopidogrel and aspirin is standard for acute coronary syndromes and percutaneous interventions.
- Despite benefits, adverse ischemic events like stent thrombosis persist.
Purpose of the Study:
- To investigate the clinical implications of variable patient responses to clopidogrel.
- To explore the association between clopidogrel nonresponsiveness and adverse clinical outcomes.
- To examine clopidogrel metabolism in light of observed response variability.
Main Methods:
- Analysis of ex vivo platelet function measurements to assess clopidogrel response.
- Review of clinical trial data regarding ischemic events in patients on antiplatelet therapy.
- Investigation into the metabolic pathways of clopidogrel.
Main Results:
- Significant variability and nonresponsiveness to clopidogrel therapy observed in patient populations.
- Preliminary evidence suggests nonresponsiveness correlates with increased risk of adverse events.
- These findings highlight the need for a deeper understanding of clopidogrel metabolism.
Conclusions:
- Patient response variability to clopidogrel is a significant clinical concern.
- Nonresponsiveness to clopidogrel may increase the risk of thrombotic events.
- Further research into clopidogrel metabolism is crucial for optimizing antiplatelet therapy.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...